Abbreviations

ABCP: Atezolizumab/bevacizumab/carboplatin/paclitaxel

AC: Atypical carcinoid

ACP: Atezolizumab/carboplatin/paclitaxel

ACTH: Adrenocorticotropic hormone

ADC: Adenocarcinoma

AE: Adverse event

AIS: Adenocarcinoma in situ

AJCC: American Joint Committee on Cancer

ALK: Anaplastic lymphoma kinase

ALL: Acute lymphoblastic leukaemia

APC: Antigen-presenting cell

ASCO: American Society of Clinical Oncology

ATP: Adenosine triphosphate

BCP: Bevacizumab/carboplatin/paclitaxel

BID: Twice daily

BSC: Best supportive care

CAR: Chimeric antigen receptor

ChT: Chemotherapy

CI: Confidence interval

CIS: Carcinoma in situ

CISH: Chromogenic in situ hybridisation

CNS: Central nervous system

COPD: Chronic obstructive pulmonary disease

CRP: C-reactive protein

CRS: Cytokine release syndrome

CRT: Chemoradiotherapy

CT: Computed tomography

ctDNA: Circulating tumour DNA

CTLA-4: Cytotoxic T-lymphocyte antigen 4

DC: Dendritic cell

DCR: Disease control rate

DFS: Disease-free survival

DoR: Duration of response

EBUS: Endobronchial ultrsound

ECOG: Eastern Cooperative Oncology Group

EGF: Epidermal growth factor

EGFR: Epidermal growth factor receptor

EMT: Epithelial mesenchymal transition

EORTC: European Organisation for Research and Treatment of Cancer

EPP: Extrapleural pneumonectomy

ERCC1: Excision repair cross-complementation group 1

ES: Extensive stage

ETOP: European Thoracic Oncology Platform

EUS: Endoscopic ultrasound

EvG: Elastica van Gieson

FDA: Food & Drug Administration

FDG: Fluorodeoxyglucose

FGFR: Fibroblast growth factor receptor

FISH: Fluorescent in situ hybridisation

FNA: Fine needle aspiration

GGO: Ground glass opacity

GSP: General secretory pathway

HE: Haematoxylin–eosin

HER2: Human epidermal growth factor receptor 2

HIAA: Hydroxyindoleacetic acid

HR: Hazard ratio

IALT: International Adjuvant Lung Cancer Trial

IARC: International Agency for Research on Cancer

IASLC: International Association for the Study of Lung Cancer

ICI: Immune checkpoint inhibitor

IDO: Indoleamine 2,3-dioxygenase

IFN: Interferon

Ig: Immunoglobulin

IHC: Immunohistochemistry

IL: Interleukin

IMRT: Intensity modulated radiotherapy

IPD: Individual patient data

ISH: In situ hybridisation

ITT: Intention to treat

LACE: Lung Adjuvant Cisplatin Evaluation

LAG-3: Lymphocyte-activation gene 3

LAR: Long-acting release

LCNEC: Large cell neuroendocrine carcinoma

LDCT: Low-dose computed tomography

LINAC: Linear accelerator

LN: Lymph node

mAb: Monoclonal antibody

MEN-1: Multiple endocrine neoplasia type 1

MHC: Major histocompatibility complex

MKI: Multikinase inhibitor

MPE: Malignant pleural effusion

MPM: Malignant pleural mesothelioma

MRI: Magnetic resonance imaging

mTOR: Mammalian target of rapamycin

nAChR: Nicotinic acetylcholine receptor

NET: Neuroendocrine tumour

NGS: Next generation sequencing

NK: Natural killer

NLST: National Lung Screening Trial

NRT: Nicotine replacement therapy

NSCLC: Non-small cell lung cancer

NSE: Neuron-specific enolase

NSQ: Nonsquamous

NTRK: Neurotrophic tyrosine receptor kinase

ORR: Objective response rate / Overall response rate

OS: Overall survival

P/D: Pleurectomy/decortication

PAH: Polycyclic aromatic hydrocarbon

PAS: Periodic acid-Schiff

PCI: Prophylactic cranial irradiation

PCR: Polymerase chain reaction

PD-1/2: Programmed cell death protein 1/2

PDGFR: Platelet-derived growth factor receptor

PD-L1/2: Programmed death-ligand 1/2

PET: Positron emission tomography

PFS: Progression-free survival

PORT: Postoperative radiotherapy

PS: Performance status

QD: Once a day

qPCR: Quantitative polymerase chain reaction

RATS: Robotic-assisted thoracic surgery

RCT: Randomised clinical trial

RECIST: Response Evaluation Criteria in Solid Tumours

RR: Response rate

RT: Radiotherapy

SABR: Stereotactic ablative radiotherapy

SBM: Solitary brain metastasis

SCC: Squamous cell carcinoma

SCLC: Small cell lung cancer

SPN: Solitary pulmonary nodule

SQ: Squamous

SR: Sleeve resection

SST: Superior sulcus tumours

TBNA: Transbronchial needle aspiration

TC: Typical carcinoid

TCR: T cell receptor

T-DM1: Ado-trastuzumab emtansine

Teff: Effector T cell

TIM-3: T cell immunoglobulin and mucin domain 3

TKI: Tyrosine kinase inhibitor

TMB: Tumour mutation burden

TMD: Transmembrane domain

TNM: Tumour, Node, Metastasis

TPC: Tunnelled pleural catheter

TRK: Tropomyosin receptor kinase

TTF1: Thyroid transcription factor 1

TTP: Time to progression

UFT: Tegafur-uracil

UICC: Union for International Cancer Control

VATS: Video-assisted thoracoscopic surgery

VDT: Volume doubling time

VEGF: Vascular endothelial growth factor

VEGFR: Vascular endothelial growth factor receptor

WBRT: Whole brain radiotherapy

WHO: World Health Organization

« Previous Page Next Page »

Last update: 12 June 2019